Patient outcome with respect to response rates and FCGR2A and FCGR3A genotype
| . | CR . | PR . | nPR . | SD . | PD . | P, CR vs non-CR . | P, responders (CR/PR/nPR) vs nonresponders . |
|---|---|---|---|---|---|---|---|
| FC | |||||||
| FCGR2A | .14 | .15 | |||||
| HH | 11 (23%) | 13 (28%) | 2 (4%) | 19 (40%) | 2 (4%) | ||
| HR | 13 (15%) | 42 (48%) | 7 (8%) | 20 (23%) | 6 (7%) | ||
| RR | 4 (9%) | 27 (59%) | 2 (4%) | 12 (26%) | 1 (2%) | ||
| FCGR3A | .39 | .98 | |||||
| VV | 5 (20%) | 9 (36%) | 3 (12%) | 6 (24%) | 2 (8%) | ||
| FV | 10 (12%) | 40 (47%) | 7 (8%) | 26 (30%) | 3 (3%) | ||
| FF | 13 (19%) | 33 (47%) | 1 (1%) | 19 (27%) | 4 (6%) | ||
| R-FC | |||||||
| FCGR2A | .86 | .44 | |||||
| HH | 11 (22%) | 26 (52%) | 4 (8%) | 7 (14%) | 2 (4%) | ||
| HR | 25 (25%) | 51 (50%) | 1 (1%) | 21 (21%) | 3 (3%) | ||
| RR | 10 (27%) | 16 (43%) | 0 (0%) | 10 (27%) | 1 (3%) | ||
| FCGR3A | .46 | .44 | |||||
| VV | 3 (18%) | 11 (65%) | 1 (6%) | 2 (12%) | 0 (0%) | ||
| FV | 21 (22%) | 48 (51%) | 4 (4%) | 18 (19%) | 4 (4%) | ||
| FF | 22 (29%) | 34 (45%) | 0 (0%) | 18 (24%) | 2 (3%) |
| . | CR . | PR . | nPR . | SD . | PD . | P, CR vs non-CR . | P, responders (CR/PR/nPR) vs nonresponders . |
|---|---|---|---|---|---|---|---|
| FC | |||||||
| FCGR2A | .14 | .15 | |||||
| HH | 11 (23%) | 13 (28%) | 2 (4%) | 19 (40%) | 2 (4%) | ||
| HR | 13 (15%) | 42 (48%) | 7 (8%) | 20 (23%) | 6 (7%) | ||
| RR | 4 (9%) | 27 (59%) | 2 (4%) | 12 (26%) | 1 (2%) | ||
| FCGR3A | .39 | .98 | |||||
| VV | 5 (20%) | 9 (36%) | 3 (12%) | 6 (24%) | 2 (8%) | ||
| FV | 10 (12%) | 40 (47%) | 7 (8%) | 26 (30%) | 3 (3%) | ||
| FF | 13 (19%) | 33 (47%) | 1 (1%) | 19 (27%) | 4 (6%) | ||
| R-FC | |||||||
| FCGR2A | .86 | .44 | |||||
| HH | 11 (22%) | 26 (52%) | 4 (8%) | 7 (14%) | 2 (4%) | ||
| HR | 25 (25%) | 51 (50%) | 1 (1%) | 21 (21%) | 3 (3%) | ||
| RR | 10 (27%) | 16 (43%) | 0 (0%) | 10 (27%) | 1 (3%) | ||
| FCGR3A | .46 | .44 | |||||
| VV | 3 (18%) | 11 (65%) | 1 (6%) | 2 (12%) | 0 (0%) | ||
| FV | 21 (22%) | 48 (51%) | 4 (4%) | 18 (19%) | 4 (4%) | ||
| FF | 22 (29%) | 34 (45%) | 0 (0%) | 18 (24%) | 2 (3%) |